Answers are grounded in this paper and cite their sources.
We report the nine-year neurological and endocrine follow-up of a woman diagnosed with juvenile myoclonic epilepsy (JME) during adolescence, whose treating neurologist noted a possible catamenial association. The patient retrospectively reported menarche at age 12 (summer 2013) anddaily awakening myoclonus lasting 15–20 min after awakening, beginning on 17 January 2014, with no meaningful improvement during lamotrigine treatment. Awakening myoclonus, dropping objects, without loss of consciousness, and a September 2017 electroencephalography (EEG) report describing 5–6 Hz epileptiform complexes supported the clinical diagnosis. Menstrual records showed cycles of 33–36 days in late 2017. Estradiol and progesterone were measured on 4 December (cycle day 5; 49.4 pg/mL and 0.27 ng/mL) and 20 December 2017 (cycle day 21; 455 pg/mL and 1.16 ng/mL). The latter sample preceded the next menstruation by 13 days, without confirmation of ovulation, and cannot establish a luteal defect or C3 (inadequate luteal-phase) catamenial pattern. Following neurological treatment adjustments in 2017, the last reported seizure occurred in October 2017, before the endocrine measurements and the subsequent dydrogesterone recommendation; seizure freedom continued after cyclic dydrogesterone was introduced in the therapeutic program. During follow-up, levetiracetam was discontinued in June 2023 and lamotrigine was gradually reduced. At the July 2026 visit, complete lamotrigine withdrawal was planned. This case illustrates the importance of accurate chronology and the distinction between suspected menstrual modulation, documented seizure remission under treatment and an untested hormonal mechanism.
No takes yet. Share an insight, caveat, or question.
Georgescu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: